Pharvaris releases CHAPTER-3 topline data presentation for deucrictibant XR Phase 3 trial

PUBT · 1d ago
Pharvaris releases CHAPTER-3 topline data presentation for deucrictibant XR Phase 3 trial
  • Pharvaris released topline Phase 3 CHAPTER-3 results for deucrictibant XR 40 mg once daily in hereditary angioedema prophylaxis.
  • Primary endpoint met with an 83% reduction in investigator-confirmed attacks versus placebo; 95% CI 72%-90%; p<0.0001.
  • Type 1/2 subgroup showed an 87% reduction in attacks; all secondary efficacy endpoints reported as statistically significant.
  • Quality-of-life improved, with AE-QoL difference versus placebo of -23.53 at Week 24; 95% CI -32.15 to -14.92; p<0.0001.
  • Safety described as well tolerated; serious adverse events 1.8% on deucrictibant XR versus 0% on placebo; no treatment-related serious events.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.